TARBP2-Enhanced Resistance during Tamoxifen Treatment in Breast Cancer

Tamoxifen is the most widely used hormone therapy in estrogen receptor-positive (ER+) breast cancer, which accounts for approximately 70% of all breast cancers. Although patients who receive tamoxifen therapy benefit with respect to an improved overall prognosis, resistance and cancer recurrence sti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ming-Yang, Huang, Hsin-Yi, Kuo, Yao-Lung, Lo, Chiao, Sun, Hung-Yu, Lyu, Yu-Jhen, Chen, Bo-Rong, Li, Jie-Ning, Chen, Pai-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406945/
https://www.ncbi.nlm.nih.gov/pubmed/30759864
http://dx.doi.org/10.3390/cancers11020210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406945/
https://www.ncbi.nlm.nih.gov/pubmed/30759864
http://dx.doi.org/10.3390/cancers11020210

Ejemplares similares